Navigation Links
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients

ill be to pursue a larger Phase II study to optimize dosing regimens. Novo Nordisk A/S holds an exclusive license to the E1-I.N.T.(TM) product and can further develop and commercialize this product in accordance with the terms of the companies' amended license agreement as previously announced July 17, 2006.

In addition, these clinical data further support and validate the potential of Transition's other gastrin based therapies to provide type 2 diabetes patients with sustained improvement in glucose control. Transition holds the exclusive rights to a series of proprietary gastrin based combination therapies including GLP1-I.N.T.(TM) (a combination of gastrin analogue, G1, and a GLP-1 analogue) and combination therapies of gastrin and DPP-IV inhibitors. Based on these encouraging findings, Transition is accelerating the development of these combination gastrin-based therapies into clinical trials.

Conference Call Details:

Transition will host a conference call to be held at 5:00pm EST on Thursday, June 28th, 2007. Dr. Sherwyn Schwartz from San Antonio Texas who was the lead investigator in this study will be available to answer any questions. The conference call can be accessed by dialing 1 (800) 633-8548. International callers are advised to dial (212) 676-5241. To participate, please dial the conference number 15 minutes prior to the beginning of the call. A replay of the conference call will be available until July 6, 2007 by visiting Transition's website www.transitiontherapeutics.com.

About the Study Design

This exploratory Phase IIa clinical study for E1-I.N.T.(TM) was a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of daily E1-I.N.T.(TM) treatments for 4 weeks with a 6-month follow-up in type 2 diabetes patients. The E1-I.N.T.(TM) treatment consisted of a combination of two agents, G1 and E1. All patie
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:8/29/2014)... 2014 The Competitive Intelligence (CI) function is ... CI leaders who adjust will succeed, and those who ... Best Practices, LLC study CI leaders from 32 biopharmaceutical ... - Use secondary research whenever possible - it,s ... - Internal staff who are creative thinkers provide the ...
(Date:8/29/2014)... -- Pomerantz LLP has filed a class action lawsuit ... EDAP ) and certain of its officers.  The ... District of New York , and ... consisting of all persons or entities who purchased EDAP ... inclusive (the "Class Period"). This class action seeks to recover ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4
... announced the initiation of a landmark Phase 2 ... developed to improve neurological function in patients with ... In accordance with its internal focus on scientific ... at a peer-attended symposium at the American Spinal ...
... April 23, 2012 Medela convened the 7th ... on April 20-21, 2012. The annual event, attended ... lactation consultants, highlighted the latest insights into breastfeeding ... supporting breastfeeding women and their families through research ...
Cached Medicine Technology:Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 2Asubio Initiates Landmark Clinical Study in Spinal Cord Injury 3Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 2Latest Findings in Breastfeeding Science Presented at Medela's 7th International Breastfeeding and Lactation Symposium 3
(Date:8/29/2014)... based on administering antidepressants for acute and chronic ... are needed to determine whether these drugs should ... basis., Dr. Ian Gilron, a professor and director ... Anesthesiology, and his team of seven researchers reviewed ... antidepressants for pain relief post-surgery would work more ...
(Date:8/29/2014)... Village, IL (PRWEB) August 29, 2014 ... in hearing wellness solutions, is on its way to ... at the San Diego Convention Center to exhibit and ... who work in high-noise industrial environments. Etymotic’s safety earphones ... hottest wearable technology devices at the show. , ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 ... “The Safety Chick” who profiled a handful of ... Earphones from Etymotic Research. This year, many schools ... and Etymotic, an innovator of hearing wellness solutions, ... Their ETY•Kids Safe-Listening Earphones, offered in yellow, pink ...
(Date:8/29/2014)... London, UK (PRWEB) August 29, 2014 ... growing ones in the in-vitro diagnostics industry; it is ... The growth is driven by the ongoing spread of ... a primary factor associated with the upsurge of opportunistic ... diagnostic; and a broader availability of immunosuppressive medicines. Although ...
(Date:8/29/2014)... Edvance360, a leading provider of eLearning ... teaching, as well as 2011 winner and six-time-finalist for ... System, announced that Brooke Education Services, Northwest Academy, Typewell, ... Advertising Bureau of Canada (IAB Canada), StarSVCS, and HMG ... delighted to welcome each new client to the growing ...
Breaking Medicine News(10 mins):Health News:Antidepressants show potential for postoperative pain 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 2Health News:Infectious Disease Testing Universe Examined in New VPG Research Report Available at MarketPublishers.com 3Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2
... price for a 30-second advertising spot in the 2012 Super Bowl ... study suggests that, for advertisers, it may not really matter if ... But for the sake of companies forking out big bucks on ... The study by an Oregon State University researcher, which is ...
... -- Teens who think of themselves as thrill-seekers and who ... likely to drive with other teens in the car, which ... finds. And a second study of teens involved in ... distraction and risky driving behavior often played a role. ...
... HealthDay Reporter , THURSDAY, Jan. 26 (HealthDay News) -- ... provide insight into whether patients are at high risk of ... cancer. The test, which is currently available, could ... prevent the cancer from returning. There are caveats: The ...
... a "common sense" decision to start the company in a ... belt. , "We wanted to give better stroke care," said ... of Neurology at the Medical College of Georgia at Georgia ... and his colleagues were frustrated that nearly five years after ...
... By Denise Mann HealthDay Reporter , THURSDAY, Jan. ... for liver cancer among people with hepatitis B, a new study ... hepatitis B virus, is one of the main causes of liver ... have shown promise in reducing risk for cancer. Other studies have ...
... a sensitive non-invasive marker of early lung disease in young ... from Australian researchers. "We found that LCI is elevated ... airway inflammation and Pseudomonas aeruginosa," said Yvonne Belessis, MBBS, MPH, ... may not only be a marker of early CF lung ...
Cached Medicine News:Health News:Sporting event ads viewed favorably - especially if the game is close 2Health News:Teen Driver's Friends Can Be Dangerous Distraction, Studies Find 2Health News:Test Might Predict Risk of Lung Cancer's Return 2Health News:Georgia Bio honors biotech company that enables stroke care 2Health News:Georgia Bio honors biotech company that enables stroke care 3Health News:Statins May Stave Off Liver Cancer in People With Hepatitis B 2Health News:Early cystic fibrosis lung disease detected by bronchoalveolar lavage and lung clearance index 2
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... To help cardiologists meet the ... Toshiba introduces the high performance Infinix ... solutions combine easy-to-use controls, one-touch operations, ... to optimize workflow and allow physicians ...
Cardiac 5-Axis Bi-plane: Infinix CF-i/BP...
... on the promise of Flat Panel ... outstanding image quality, at lower doses, ... small devices and structures. The new ... at lower dose than other systems ...
Medicine Products: